Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06024239 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)

A Phase 1 study of Healthy Volunteers and Generalized Anxiety Disorder (GAD), sponsored by AbbVie.

Completed
Registry status
Phase 1
Development phase
72
Enrollment target
3
Study locations

NCT06024239 is a Phase 1 study of Healthy Volunteers and Generalized Anxiety Disorder (GAD) that has completed, run by AbbVie. The registered enrollment target is 72 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06024239, a Phase 1 study of Healthy Volunteers and Generalized Anxiety Disorder (GAD), has completed, sponsored by AbbVie.

COMPLETED
Registry status
Phase 1
Development phase
72 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to assess the pharmacokinetics, safety, and tolerability following multiple ascending oral doses of ABBV-932 or placebo in healthy adult participants, participants with Generalized Anxiety Disorder (GAD), and participants with bipolar disorder (BPD).

Conditions Studied

Healthy Volunteers Generalized Anxiety Disorder (GAD) Bipolar Disorder (BPD)

Interventions

  • DRUG ABBV-932
  • DRUG Placebo for ABBV-932

Study Locations (3)

California

  • Collaborative Neuroscience Research CNS /ID# 260270 - Los Alamitos

Illinois

  • Acpru /Id# 255945 - Grayslake

New Jersey

  • Hassman Research Institute Marlton Site /ID# 260271 - Marlton

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2023-08-31
Est. Completion 2025-03-04
Phase Phase 1

Sponsor

AbbVie

526 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06024239

The ClinicalTrials.gov registry entry for NCT06024239 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (85% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Healthy Volunteers appearing as the primary indexed condition, and to 2 interventions - of which ABBV-932 is the first listed.

NCT06024239 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Illinois, New Jersey.

Frequently Asked Questions

What is clinical trial NCT06024239 about?

NCT06024239 is a clinical study titled "A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)". The purpose of this study is to assess the pharmacokinetics, safety, and tolerability following multiple ascending oral doses of ABBV-932 or placebo in healthy adult participants, participants with Generalized Anxiety Disorder (GAD), and participants with bipolar disorder (BPD).

What is the current status of trial NCT06024239?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2023-08-31. Estimated completion is 2025-03-04.

What conditions does trial NCT06024239 study?

This clinical trial studies the following conditions: Healthy Volunteers, Generalized Anxiety Disorder (GAD), Bipolar Disorder (BPD).

What interventions are being tested in trial NCT06024239?

The interventions under investigation include: ABBV-932 (DRUG), Placebo for ABBV-932 (DRUG).

Who is sponsoring clinical trial NCT06024239?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06024239 being conducted?

This trial has 3 study locations across California, Illinois, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Healthy Volunteers

All registered trials for this condition

Generalized Anxiety Disorder (GAD)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.